Omios Biologics

Principal Investigators: Ian J. Mohr, PhD

Omios Bio is developing next-generation oncolytic virus therapy to treat solid tumors. Cancer is a complex disease that requires complex therapies. Our patented platform technology uses a novel vaccinia virus to target cancer cell mutations in cell death programs offering exceptional cancer selectivity, and maximum cancer cell destruction. Omios OV therapy overcomes limitations of current therapies by directly reaching metastases in a selective way, have an improved tolerability, no resistance, prevent relapse, and offer a durable effect. With a strong team, proven technology, and a large market opportunity, Omios is poised to revolutionize cancer treatment.